Lantheus secures FDA fast track designation for prostate cancer drug

2022 10 21 23 21 9342 Prostate Cancer 3 D Rendering 400

Lantheus Medical Imaging parent company Lantheus Holdings and partner Point Biopharma Global have secured fast-track designation from the U.S. Food and Drug Administration (FDA) for lutetium-177 (Lu-177) PNT2002, a radiopharmaceutical for the treatment of metastatic, castration-resistant prostate cancer.

Lantheus licensed exclusive marketing rights for the agent from Point Biopharma Global in December of last year, it said.

Page 1 of 460
Next Page